Overview

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib
Criteria
Inclusion Criteria:

Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the
surveillance.

Exclusion Criteria:

Patients not administered SUNITINIB MALATE(Sutent).